证券代码：002793 证券简称：罗欣药业 公告编号：2026-019 罗欣药业集团股份有限公司 关于为控股子公司提供担保的进展公告 二、担保进展情况 近日，上海罗欣向上海浦东发展银行股份有限公司上海自贸试验区分行（以 下简称"浦发银行"）申请流动资金贷款 1,000 万元，公司为该笔借款提供连带 责任保证担保，上海市中小微企业政策性融资担保基金管理中心（以下简称"融 资担保中心"）为上述 1,000 万元借款中 85%的部分提供连带责任保证担保，同 时公司向融资担保中心提供反担保。本次担保及反担保事项在前述审议的额度范 围内，无需另行召开董事会或股东会审议。 1 上海罗欣不是失信被执行人，其生产经营活动正常，资信状况良好。本次担 保前公司及子公司对上海罗欣的担保余额为 1,500.00 万元，本次担保后公司及子 公司对上海罗欣的担保余额为 2,500.00 万元，本次担保后上海罗欣可用担保额度 剩余 3,600.00 万元。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 罗欣药业集团股份有限公司（以下简称"公司""上市公司"）及控股子公 司对外 ...

证券代码：002793 证券简称：罗欣药业 公告编号：2026-018 罗欣药业集团股份有限公司 关于为控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1 的担保余额为 121,439.37 万元，本次担保后山东罗欣可用担保额度剩余 21,825.65 万元。 三、被担保人基本情况 公司名称：山东罗欣药业集团股份有限公司 公司类型：股份有限公司（港澳台投资、未上市） 罗欣药业集团股份有限公司（以下简称"公司""上市公司"）及控股子公 司对外担保总额超过最近一期经审计净资产 100%；公司及控股子公司担保金额 超过上市公司最近一期经审计净资产 50%，提请投资者充分关注担保风险。 一、担保情况概述 公司及控股子公司为满足日常生产经营及业务拓展资金需要，保证其生产经 营持续发展和业务顺利开展，2025 年度拟为控股子公司提供总额度不超过人民 币 6.48 亿元的担保（不含单事单议和已履行董事会和股东大会审议程序的担保 额度）。其中，公司为山东罗欣药业集团股份有限公司（以下简称"山东罗欣"） 提供担保额度人民币 50,500 ...

证券代码：002793 证券简称：罗欣药业 公告编号：2026-017 罗欣药业集团股份有限公司 关于为控股子公司银行借款提供反担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 罗欣药业集团股份有限公司（以下简称"公司""上市公司"）及控股子公司对外 担保总额超过最近一期经审计净资产 100%；公司及控股子公司担保金额超过上市公 司最近一期经审计净资产 50%，提请投资者充分关注担保风险。 一、反担保情况概述 近日，公司与浦东科技在上海市签署了《反担保合同》，上海罗欣向宁波银行贷 款本金人民币捌佰万元，浦东科技为上海罗欣提供担保，公司以连带保证的方式就上 海罗欣上述债务向浦东科技提供连带责任保证反担保。本次反担保事项在前述审议的 额度范围内，无需另行召开董事会或股东会审议。 上海罗欣不是失信被执行人，其生产经营活动正常，资信状况良好。本次担保后 公司对上海罗欣的反担保余额为800万元，上海罗欣可用反担保额度剩余0万元。 1 三、被担保方基本情况 公司名称：罗欣药业（上海）有限公司 企业类型：有限责任公司（自然人投资或控股的法人独资） ...

Core Viewpoint - The acquisition of a minority stake in Beijing Health Technology Co., Ltd. by Luoxin Pharmaceutical aims to optimize governance structure and enhance operational efficiency, allowing the company to fully control its subsidiary and potentially increase shareholder value through improved profitability and market expansion [1][2]. Group 1: Acquisition Details - Luoxin Pharmaceutical plans to acquire a 19.0526% stake in Beijing Health for 67.56052 million yuan, increasing its ownership from 80.9474% to 100% [1]. - The acquisition will not change the scope of the company's consolidated financial statements, as Beijing Health will continue to be included [1]. Group 2: Financial Performance and Projections - Beijing Health reported a net profit of 81.8476 million yuan from January to October 2025, indicating a strong profitability trend [2]. - The core product, Tai Xin Zan, has achieved sales exceeding 630 million yuan and is expected to see explosive growth in 2026 due to new indications being included in medical insurance [1][2]. Group 3: Strategic Initiatives - Luoxin Pharmaceutical is exploring diverse sales channels for innovative drugs, including partnerships with pharmacies and e-commerce platforms, with plans to expand nationwide by 2026 [2]. - The company has multiple innovative drugs in development, including LX22001 and Pucanotide, which could fill market gaps and become significant revenue drivers [3]. Group 4: Market Position and Competitive Advantage - The successful commercialization of Tai Xin Zan has allowed Luoxin Pharmaceutical to build a robust marketing system for innovative drugs, enhancing its market competitiveness [3]. - The acquisition of Beijing Health is expected to improve shareholder returns and stimulate market enthusiasm, thereby increasing investor expectations [2].

Group 1 - The core point of the article is that Luoxin Pharmaceutical reported its latest total number of shareholders as 37,614 as of February 13, 2026 [2]

罗欣药业集团股份有限公司 关于受让控股子公司少数股东股权暨关联交易的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002793 证券简称：罗欣药业 公告编号：2026-016 8、经营范围：一般项目：技术服务、技术开发、技术咨询、技术交流、技 术转让、技术推广；货物进出口；化妆品零售；卫生用品和一次性使用医疗用品 销售；体育用品及器材零售；企业管理咨询；信息咨询服务（不含许可类信息咨 询服务）；广告设计、代理；健康咨询服务（不含诊疗服务）。（除依法须经批 准的项目外，凭营业执照依法自主开展经营活动）许可项目：食品销售；药品零 售；药品互联网信息服务；医疗器械互联网信息服务。（依法须经批准的项目， 经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可 证件为准）（不得从事国家和本市产业政策禁止和限制类项目的经营活动。） 一、本次关联交易事项概述 罗欣药业集团股份有限公司（以下简称"公司"）于 2026 年 2 月 12 日召开 第六届董事会第二次会议，以 5 票同意、0 票反对、0 票弃权、2 票回避的表决 结果，审议通过 ...

Core Viewpoint - The company, Luoxin Pharmaceutical, plans to acquire a 19.0526% stake in Beijing Health Technology from Chengdu Deyi for 67.56 million yuan, increasing its ownership in Beijing Health from 80.9474% to 100% [1][7] Group 1: Acquisition Details - The acquisition is classified as a related party transaction since Chengdu Deyi and its concerted parties hold more than 5% of the company's shares [1][7] - Beijing Health serves as the sales and promotion platform for Luoxin's main products, focusing on drug wholesale and promotion [1][7] - The registered capital of Beijing Health has increased from 33.33 million yuan to 353.6 million yuan over time, with Luoxin's stake decreasing before this acquisition [1][7] Group 2: Financial Performance of Beijing Health - For the period from January to October 2025, Beijing Health reported revenues of 638.71 million yuan, a 16.12% increase from the full-year revenue of 550.05 million yuan in 2024 [3][9] - The net profit for the same period was 81.85 million yuan, marking a turnaround from previous losses, with positive cash flow from operating activities of 19.79 million yuan [3][9] Group 3: Luoxin Pharmaceutical's Financial Overview - In the first three quarters of 2025, Luoxin's revenue was 1.723 billion yuan, a decrease of 8.37% year-on-year, while the net profit attributable to shareholders was 22.93 million yuan, an increase of 108.64% [11] - The company reported a significant increase in cash flow from operating activities, amounting to 280 million yuan, a 272.42% rise compared to the previous year [11] - Luoxin anticipates a narrowed loss for the full year 2025, projecting a net profit of approximately -340 million to -250 million yuan [12]

Core Viewpoint - The company, Luoxin Pharmaceutical, plans to acquire a 19.0526% stake in Beijing Luoxin Health Technology Co., Ltd. for 67.56 million yuan, increasing its ownership from 80.9474% to 100% [1] Group 1: Transaction Details - The acquisition is classified as a related party transaction since Chengdu Deyi holds more than 5% of Luoxin Pharmaceutical's shares [1] - The transaction price is based on an assessed value of 354.6 million yuan for the total equity of Beijing Health as of October 31, 2025, reflecting an increase of 538.57 million yuan [3] - The acquisition aims to optimize resource allocation and enhance operational decision-making efficiency, aligning with the company's long-term development strategy [3] Group 2: Financial Performance of Beijing Health - For the period from January to October 2025, Beijing Health reported a revenue of 63.87 million yuan, a 16.12% increase from the full-year revenue of 55.00 million yuan in 2024 [2] - The net profit for the same period was 8.18 million yuan, marking a turnaround from a loss of 15.41 million yuan in 2024 [2] - The net cash flow from operating activities was 1.98 million yuan, indicating a positive shift from negative cash flow in the previous year [2] Group 3: Company Financials and Challenges - Luoxin Pharmaceutical has faced significant losses over recent years, with net profits of -1.448 billion yuan, -639 million yuan, and -768 million yuan from 2022 to 2024, totaling approximately -2.855 billion yuan [5] - The company's revenue has declined from 6.478 billion yuan in 2021 to 2.647 billion yuan in 2024, although there was a slight recovery in 2024 [5] - The company anticipates a narrowed loss for the fiscal year 2025, projecting a net profit of between -340 million yuan and -250 million yuan [5]

Core Viewpoint - Recently, Luoxin Pharmaceutical (002793) announced plans to acquire a 19.0526% stake in Luoxin Health Technology (Beijing) Co., Ltd. from Chengdu Deyixinhua Equity Investment Partnership (Limited Partnership) for 67.56 million yuan, increasing its ownership from 80.9474% to 100% [1] Group 1 - The transaction is valued at 67.56 million yuan, corresponding to Chengdu Deyixin's paid-in capital of 67.37 million yuan [1] - The completion of this transaction will result in Luoxin Pharmaceutical holding a full 100% stake in Luoxin Health Technology [1] - This transaction is classified as a related party transaction, as Chengdu Deyixin and its concerted parties hold more than 5% of Luoxin Pharmaceutical's shares [1]

Core Viewpoint - The company plans to acquire a 19.0526% stake in Beijing Health Technology Co., Ltd. from Chengdu Deyixin Huagu Equity Investment Partnership for 67.56052 million yuan, increasing its ownership in Beijing Health from 80.9474% to 100% [1] Group 1: Acquisition Details - The acquisition will be funded through the company's own or raised funds [1] - The stake corresponds to Chengdu Deyixin's paid-in capital of 67.37 million yuan [1] - The transaction is aimed at consolidating resources and enhancing operational decision-making efficiency [1] Group 2: Company Background - Beijing Health was established in December 2020 and serves as the sales and promotion platform for the company's main products [1] - The company focuses on the circulation of high-quality pharmaceuticals in the fields of digestive and anti-infective drugs [1] - Beijing Health has achieved profitability and its future earning capacity and operational risks are reliably estimable [1] Group 3: Strategic Implications - The acquisition aligns with the company's long-term development strategy and is expected to enhance synergy with its quality subsidiaries [1] - It is seen as beneficial for optimizing resource allocation and advancing the company's development strategy [1]